Center for Cancer Research hosts 10th Annual GIST Clinic

Jul 14, 2017

Patients and specialists from around the world gathered for the 10th Annual Pediatric and Wildtype GIST Clinic, which took place Wednesday, July 5 through Friday, July 7, 2017 at the NIH Clinical Center in Bethesda, Maryland. Occurring once a year, the clinic convenes clinicians, research scientists and advocates from across the country to consult with patients who have GIST. Christine Gonzales, a GIST clinic patient from New Mexico, says, “It’s been super amazing because I’ve never talked to a specialist about this cancer."

Sarcoma Awareness Month

Jun 30, 2017

To recognize Sarcoma Awareness Month this July, we are highlighting our researchers who are advancing research discovery in this field. Learn more...

Gliomatosis Cerebri International logo

2nd International Gliomatosis Cerebri Working Group Conference

Jun 27, 2017

On June 22-23, the NIH hosted the 2nd Gliomatosis Cerebri International Conference that brought together leading neuro-oncologists, neuroscientists and families who have lost a child to the disease. Learn more...

NCI RNA Biology 2017 symposium recap

May 3, 2017

The recent discovery of new classes of RNAs and the demonstration that alterations in RNA metabolism underlie numerous human cancers have resulted in enormous interest among CCR investigators in RNA biology. In order to share the latest research in this exciting field, the CCR Initiative in RNA Biology held its second international symposium April 23-24, 2017, in Natcher Auditorium. Learn more...

Tom Uldrick discusses Castleman’s disease with The Huffington Post

Apr 10, 2017

Tom Uldrick, M.D., Senior Clinican in the HIV and AIDS Malignancy Branch, studies Castleman’s, a rare and aggressive disease, and discussed some of his work with The Huffington Post. He is on the advisory board of the Castleman Disease Collaborative Network (CDCN), which brings researchers from around the world to advance treatment and research for the disease.  Dr. Uldrick  treats David Fajgenbaum, M.D., who founded CDCN and is fighting the disease. It was Dr. Uldrick who gave Fajgenbaum the idea to try singling out specific drugs to test how they work for Castleman disease patients.  Learn more...

Tom Uldrick discusses Castleman’s disease with The Huffington Post

Foregut cancers get new attention at CCR

Mar 27, 2017

The newly formed NIH Foregut Team will focus on cancers of the esophagus, stomach, pancreas, liver, bile ducts and part of the small intestine. Although these tumors are not the most common types of cancers, they are among the deadliest. Learn more...

New publication highlights 2016-2017 CCR research advances

Mar 17, 2017

Milestones is the Center for Cancer Research’s new annual publication that highlights some of the top cancer-research milestones CCR investigators have reached in the last year. The collection presented here merely scratches the surface of the many advances made by CCR scientists but provides a window into the broad spectrum of our activities and the ingenuity of our scientists. Read more...

New publication highlights 2016-2017 CCR research advances

German Minister of Health and scientists tour Clinical Center

Mar 17, 2017

CCR had the privilege of welcoming a number of German dignitaries this week. The German Minister of Health, Hermann Gröhe, and the German State Secretary for Education and Research, Dr. George Schütte, toured the NIH Clinical Center on Wednesday, March 15, 2017. They spoke with Brigitte Widemann, M.D., and toured Jack Shern’s lab in the Pediatric Oncology Branch and visited Peter Choyke, M.D., F.A.C.R., in the Molecular Imaging Clinic and discussed clinical trials with Caryn Steakley, R.N., M.S.W, Deputy Clinical Dirctor. Another group of German scientists met with CCR investigators Glenn Merlino, Ph.D., Natasha Caplen, Ph.D., Tim Greten, M.D., Kevin Camphausen, M.D. and Louis Staudt, M.D., Ph.D. The group met to discuss ongoing research in the CCR and explore areas for future collaboration.

shot and vial

Andrea Apolo discusses FDA approval of nivolumab

Mar 3, 2017

The FDA approved nivolumab for bladder cancer on February 2, and Andrea Apolo, M.D., Investigator in the Genitourinary Malignancies Branch, discussed what this means for patients on the Cancer Currents blog. Nivolumab is a drug that works with the immune system to slow or stop the growth of cancer cells. “The approval of nivolumab is an affirmation of the important role that immunotherapy plays in the treatment of advanced bladder cancer,” Dr. Apolo said in the blog.  Read more...

Andrea Apolo discusses FDA approval of nivolumab

Congressional members visit CCR

Feb 8, 2017

We were honored to welcome Rep. Tom Cole (R-OK) and members of the House Appropriations Committee, Labor and Health and Human Services (L-HHS) Subcommittee and provide them with a tour of our Molecular Imaging Program. Rep. Cole, Chairman of the L-HHS Subcommittee, was joined by Rep. Andrew Harris (R-MD), Rep. Jaime Herrera Beutler (R-WA), Rep. John Moolenaar (R-MI), Rep. Nita Lowey (D-NY), Rep. Rosa DeLauro (D-CT) and Rep. Barbara Lee (D-CA). 

Pages